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Abstract
Purpose: To assess the lacrimal glands in patients with thyroid eye disease with diffusion-weighted magnetic reso-
nance (MR) imaging.
Material and methods: This study was carried out on 44 consecutive patients (17 males, 27 females, with mean age  
36 years) with thyroid eye disease and 20 age- and sex-matched volunteers. They underwent diffusion-weighted MR 
imaging of the orbit. The apparent diffusion coefficient (ADC) values of the lacrimal glands were calculated and 
correlated with the clinical activity score (CAS).
Results: The mean ADC of lacrimal glands in thyroid eye disease (1.73 × 10–3 mm2/s) was significantly higher  
(p = 0.001) than that of volunteers (1.52 × 10–3 mm2/s). The cutoff ADC value of lacrimal gland used for differentia-
tion of thyroid eye disease from volunteers was 1.62 × 10–3 mm2/s with an area under the curve value of 0.95 and an 
accuracy of 96%. There was significant difference (p = 0.03) in the ADC of the lacrimal glands in patients with active 
(n = 24) and inactive (n = 20) disease. The cutoff ADC value of the lacrimal gland used to suspect active disease was 
1.76 × 10–3 mm2/s with an area under the curve value of 0.80 and an accuracy of 82%. There was positive correlation 
between the ADC value of the lacrimal glands and CAS (r = 0.73, p = 0.001).
Conclusions: The ADC of the lacrimal glands is a non-invasive imaging parameter that can be used for diagnosis of 
thyroid eye disease and to predict the active form of the disease.
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Introduction
Thyroid eye disease is an autoimmune inflammatory dis-
order of the orbit that occurs in 25-80% of patients with 
Graves’ disease. Most patients with thyroid eye disease 
have some degrees of dryness of the eye. There is strong 
correlation between the presence of thyroid antibodies 
and lacrimal dysfunction. Lacrimal gland enlargement in 
thyroid eye disease is due to antibody-induced inflamma-
tion that can result in dry eye. The increase of the lacrimal 
gland volume correlates with an increase of proptosis and 
subjective tearing [1-3]. Few studies discuss the lacrimal 
gland involvement in thyroid eye disease. Computed to-
mography and isotope study are used to assess lacrimal 
glands in patients with thyroid eye disease; however, they 
are associated with radiation exposure [4-9].
Diffusion-weighted magnetic resonance (MR) im-
aging provides characterisation of soft tissues and their 
physiological processes because it reflects the random 
motion of water protons, which is disturbed by intracel-
lular organelles and macromolecules located in the tissues 
[10,11]. Diffusion-weighted MR imaging is used for char-
acterisation of orbital [12-14] and thyroid lesions [15,16]. 
Few studies discuss diffusion-weighted and diffusion ten-
sor imaging of the extra-ocular muscles [17-20] and the 
optic nerves [21,22] in patients with thyroid eye disease. 
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To our knowledge, there is no previous study in the Eng-
lish literature that discusses diffusion-weighted MR im-
aging of the lacrimal glands in patients with thyroid eye 
disease.
The aim of this work is to assess the lacrimal glands in 
patients with thyroid eye disease with diffusion-weighted 
MR imaging.
Material and methods
Retrospective analysis was done on 44 consecutive patients 
(17 males and 27 females aged from 18 years to 52 years 
with a mean age of 38 ± 12.6 years) with thyroid eye dis-
ease and 20 age- and sex-matched volunteers (eight males 
and 12 females with a mean age of 33.5 ± 1.3 years). 
The inclusion criteria were patients with thyroid eye dis-
ease according to diagnostic criteria for Graves’ ophthal-
mopathy [23]. The volunteers were age and sex matched 
with the patient groups, without thyroid abnormality. MR 
imaging of the orbit was done for patients and volunteers, 
and the clinical activity score (CAS) was done for patients. 
The study was approved by an institutional review board, 
and informed consent was waived because this was a ret-
rospective study.
Clinical activity score of the patients
The clinical assessment of patients was done by one endo-
crinologist (EA) who had been an expert in endocrinol-
ogy for 10 years. Patients were questioned regarding the 
symptoms of the orbit, and the ocular changes were grad-
ed in accordance with the clinical activity score (CAS) 
[24]. Patients were subdivided according to CAS into pa-
tients with active thyroid eye disease when the CAS was 
more than 3 (n = 24) and patients with inactive thyroid 
eye disease when the CAS was 3 or less (n = 20).
Magnetic resonance imaging
Magnetic resonance imaging was performed on a 1.5 Te-
sla MR machine (symphony; Siemens Medical systems, 
Erlangen, Germany) using a head circular polarisation 
surface coil. All patients underwent T1-weighted imag-
es (TR/TE of 800/15 ms) and T2-weighted fast spin echo 
images (TR/TE = 4500/80 ms) with a section thickness of 
3 mm, an inter-slice gap of 1 mm, and a field of view (FOV) 
of 20 × 25 cm. The images were obtained in the transverse 
plane. Diffusion-weighted MR imaging was done using 
a multislice echoplanar imaging sequence. Imaging pa-
rameters were; TR/TE 10.000/108 ms, FOV 20 × 25 cm, 
acquisition matrix 256 × 128, and section thickness 3 mm 
with interstice gap 1 mm. Diffusion-weighted MR images 
were acquired with diffusion-weighted factor, factor b of 
0, 500, and 1000 s/mm2 and apparent diffusion coefficient 
(ADC) maps were generated. The data acquisition time for 
the diffusion-weighted images was one minute.
Image analysis
Image analysis was performed by one radiologist with 
25 years of experience in the head and neck, who was 
blinded to the clinical findings. A region of interest (ROI) 
was placed in the lacrimal gland using the electronic 
cursor (Figure 1), and the ADC values of both lacrimal 
glands were calculated.
Statistical analysis
The statistical analysis of data was done by using PSS pro-
gram (Statistical Package for Social Science version 20). 
The Wilcoxon signed rank test proved there was an in-
significant difference in the ADC values of both lacrimal 
glands. The ADC values of both lacrimal glands were 
averaged for each patient. The data were shown in the 
form of mean and standard deviation (SD). The analysis 
of data was done to test statistical significant difference. 
Student’s t-test was used to compare between two groups. 
The receiver operating characteristic (ROC) curve was 
done to determine the cutoff point of the ADC value of 
the lacrimal gland used to differentiate thyroid eye disease 
from controls and patients with active and inactive disease 
with calculation of area under the curve (AUC). Spear-
man’s-rank correlation test was used to correlate the ADC 
value of the lacrimal glands with the CAS. The correlation 
coefficient r and p value were calculated. The p value was 
considered significant if ≤ 0.05 at 95% confidence interval.
Results
The mean ADC value of the lacrimal glands in patients with 
thyroid eye disease was 1.73 ± 0.08 (1.61-1.92) × 10–3 mm2/s 
and in volunteers was 1.52 ± 0.04 (1.44-1.68) × 10–3 mm2/s. 
There was a statistically significant difference in the ADC 
values of the lacrimal glands between patients with thyroid 
eye disease and volunteers (p = 0.001). When ADC value of 
1.62 × 10–3 mm2/s of the lacrimal glands was used as 
a threshold value for differentiating thyroid eye disease from 
volunteers, the best result was obtained with an AUC of 0.95, 
Figure 1. Region of interest (ROI) localisation: apparent diffusion coefficient 
(ADC) map shows ROI localisation of lacrimal gland
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accuracy of 96%, sensitivity of 97%, specificity of 95%, PPV 
of 97%, and NPV of 95% (Figure 2).
The CAS of patients with active disease (n = 24) was 
4.4 ± 0.4 and for patients with inactive disease (n = 20) it 
was 1.42 ± 0.3 with significant difference (p = 0.001). There 
was a significant difference (p = 0.001) in the ADC value 
of the lacrimal glands in patient with active disease [1.83 ± 
0.08 (1.62-1.92) × 10–3 mm2/s] compared to patients with 
inactive disease [1.69 ± 0.04 (1.61-1.76) × 10–3 mm2/s]. 
The cutoff ADC value of the lacrimal gland used to predict 
active disease was 1.76 × 10-3 mm2/s with an AUC of 0.80, 
an accuracy of 82%, sensitivity of 65%, specificity of 100%, 
PPV of 100%, and NPV of 73% (Figure 2). There was pos-
itive correlation between the ADC value of the lacrimal 
glands and CAS (r = 0.78, p = 0.001).
Discussion
The major findings in this study are that the ADC value of 
the lacrimal glands is higher in patients with thyroid eye 
disease than that of controls, and there is a significant dif-
ference in the ADC value of the lacrimal glands between 
active and inactive disease. There is positive correlation 
between the ADC values of the lacrimal glands and CAS.
In this work, the ADC value of lacrimal glands in 
patients with thyroid eye disease is significantly higher 
(p = 0.001) than that of volunteers. This is explained by 
excess production of hydrophilic glycosaminoglycan caus-
ing retention of the water molecules within the lacrimal 
glands, and because there is an increase in the diffusion 
space of water protons in the extracellular and an increase 
in the intracellular dimensions of the lacrimal glands 
in thyroid eye disease, which increase the diffusivity of 
the gland [17-22]. Previous studies that applied diffu-
sion-weighted MR imaging of the extra-ocular muscles 
reported that the ADC values of the extra-ocular muscles, 
especially the medial and lateral rectus muscle, are signif-
icantly higher in patients with thyroid eye disease than in 
healthy volunteers [18-20]. Another study applied diffu-
sion tensor imaging of the optic nerve and added that the 
mean, axial, and radial diffusivities of the optic nerve are 
lower in patients with thyroid eye disease compared with 
the controls (p = 0.05) [22], and the mean diffusivity levels 
correlated with changes in the visual field and the degree 
of proptosis [21].
In this work, the ADC value of the lacrimal glands is 
higher in active than in inactive form of the disease. This 
may be attributed to an active phase, histologically char-
acterised by mononuclear cell infiltrations, proliferating 
fibroblasts, oedema and enlargement of orbital muscles 
many times their normal size, and inactive or chronic 
phase, identified by fibrosis and fatty infiltrations, caus-
ing extension of fibrous strands into the adjacent adipose 
tissue. Another study added that many factors might in-
fluence the ADC values within the extra-ocular muscles 
in thyroid eye disease, including oedema, fibrosis, infiltra-
tion of the inflammatory cells, and deposition of glycos-
aminoglycans [19]. In the acute stage, the diffusivities of 
the medial rectus muscle increase compared with chronic 
stage but do not reach a significant level [17].
In this study, there was correlation between the ADC 
value of the lacrimal glands and the CAS. A previous 
study reported that n-ADC of the extra-ocular muscles 
correlated with CAS and the muscle dysfunction score 
Figure 2. Receiver operating characteristic (ROC) curve: A) The cutoff apparent diffusion coefficient (ADC) value of the lacrimal gland used for differentiation 
of thyroid eye disease from volunteers is 1.62 × 10–3 mm2/s with AUC of 0.95 and accuracy of 96%. B) The cutoff value of ADC value of the lacrimal gland 
used to predict active thyroid eye disease is 1.76 × 10–3 mm2/s with AUC of 0.80 and an accuracy of 82%
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(p = 0.001) [19]. The radial diffusivity of the medial rec-
tus muscle was significantly higher in patients (p = 0.010) 
and correlated with the muscle thickness (r = 0.349, 
p = 0.027) [17]. Another study found that there is no 
correlation between the ADC values and the CAS at the 
time of diagnosis [18]. The axial diffusivity of the optic 
nerve is positively correlated with exophthalmos degree 
(r = 0.363, p = 0.025) [22]. Another study added that there 
is no significant correlation between the ADC value and 
the signal intensity of the muscle in routine MR imaging 
and the CAS [25]. The CAS categorised patients with thy-
roid eye disease into active or inactive disease. The patients 
are scored for two symptoms of pain and five soft tissue 
inflammatory signs, totalling seven points [1-3]. The CAS 
is a valid score because there is correlation between pre-
treatment CAS and response to the immunomodulation. 
The CAS is useful for assessment of activity, but it is less 
useful for monitoring changes over time [2-5].
There are some limitations of this study. First, this 
study used diffusion-weighted MR imaging. Further 
studies with multi-parametric MR imaging [26-34] with 
reduced volume of view and monitoring the patients after 
therapy [35,36] are needed in the future. Second, ROI was 
applied for calculation of the ADC value. Future studies 
with application of advanced post processing with ma-
chine learning and texture analysis will improve the re-
sults [37-41].
We concluded that the ADC of the lacrimal glands can 
be used for diagnosis of thyroid eye disease and prediction 
of the active form of the disease.
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